US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telomir Pharmaceuticals

1.27

-0.0500-3.79%

Volume:81.82K

Turnover:104.25K

Market Cap:43.66M

PE:-3.85

High:1.32

Open:1.31

Low:1.25

Close:1.32

52wk High:3.23

52wk Low:1.05

Shares:34.38M

Float Shares:15.33M

Volume Ratio:0.91

T/O Rate:0.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3300

EPS(LYR):-0.3300

ROE:-317.65%

ROA:-152.03%

PB:7.38

PE(LYR):-3.85

Loading ...

Overview Company News Filings

Telomir Pharmaceuticals Reports Positive Safety Results for Lead Drug Candidate Telomir-1

Telomir-1 Lowers PSA Levels and Reduces Tumor Volume in Prostate Cancer Studies

Telomir Pharmaceuticals Director Craig Eagle Resigns

Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy

Telomir Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting of Stockholders

Telomir-1 Kills Aggressive Human Leukemia Cells in Preclinical Study

Telomir Pharmaceuticals Unveils Promising Preclinical Data

Telomir-1 Outperforms Deferoxamine in Reducing Intracellular Iron in Human Cells

Telomir Pharmaceuticals Q3 EPS $(0.03) Beats $(0.07) Estimate

Telomir Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview

Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data

Telomir Pharmaceuticals Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model

Telomir Pharmaceuticals to Acquire TELI Pharmaceuticals in Stock-for-Stock Deal

Telomir Pharmaceuticals: on Oct 17, Entered Loi to Acquire All Shares of Teli Pharmaceuticals Through Stock-for-Stock Exchange - SEC Filing

THOMSON REUTERS

Telomir Pharmaceuticals: Loi Provides for 6-Month Lockup Period on Telomir Shares to Be Issued to Teli Shareholders

THOMSON REUTERS

Telomir Pharmaceuticals: Transaction Consolidates Global Rights to Telmir-1 for Cancer and Aging

THOMSON REUTERS

Telomir Pharmaceuticals Reports Telomir-1 Kills Aggressive Pancreatic Cancer Cells in Preclinical Study

Telomir Pharmaceuticals Shares up 24% After Co Reports Breast Cancer Therapy Data

THOMSON REUTERS

Telomir Pharmaceuticals Inc: Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

THOMSON REUTERS

Telomir Pharmaceuticals: Plans to Expand Studies to Pancreatic, Leukemia Models, Conduct Further Animal Studies for Ind Submission - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TELO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TELO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","market":"US","secType":"STK","nameCN":"Telomir Pharmaceuticals","latestPrice":1.27,"timestamp":1775158483560,"preClose":1.32,"halted":0,"volume":81818,"delay":0,"changeRate":-0.03787878787878791,"floatShares":15328300,"shares":34380971,"eps":-0.33,"marketStatus":"Trading","change":-0.05,"latestTime":"04-02 15:37:30 EDT","open":1.31,"high":1.32,"low":1.25,"amount":104246.09743240001,"amplitude":0.05303,"askPrice":1.28,"askSize":114,"bidPrice":1.27,"bidSize":214,"shortable":3,"etf":0,"ttmEps":-0.33,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775160000000},"marketStatusCode":2,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":1.32,"preHourTrading":{"tag":"盘前","latestPrice":1.31,"preClose":1.32,"latestTime":"09:25 EDT","volume":508,"amount":641.1695076,"timestamp":1775136300070,"change":-0.01,"changeRate":-0.007576,"amplitude":0.036742},"postHourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.32,"latestTime":"19:55 EDT","volume":1664,"amount":2107.4172,"timestamp":1775087729220,"change":-0.06,"changeRate":-0.045455,"amplitude":0.045455},"volumeRatio":0.907128},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","floatShares":15328300,"roa":"-152.03%","roe":"-317.65%","lyrEps":-0.329999,"volumeRatio":0.907128,"shares":34380971,"dividePrice":0,"high":1.32,"amplitude":0.05303,"preClose":1.32,"low":1.25,"week52Low":1.05,"pbRate":"7.38","week52High":3.23,"institutionHeld":0,"latestPrice":1.27,"committee":0.304878,"eps":-0.33,"divideRate":0,"volume":81818,"delay":0,"ttmEps":-0.33,"open":1.31,"prevYearClose":1.33,"prevWeekClose":1.25,"prevMonthClose":1.3,"prevQuarterClose":1.3,"fiveDayClose":1.26,"twentyDayClose":1.3,"sixtyDayClose":1.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TELO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-17","symbol":"TELO","fiscalQuarterEnding":"2025/12","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1773720000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-11-10","symbol":"TELO","fiscalQuarterEnding":"2025/09","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2025-08-14","symbol":"TELO","fiscalQuarterEnding":"2025/06","expectedEps":-0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2025-05-14","symbol":"TELO","fiscalQuarterEnding":"2025/03","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2025-02-04","symbol":"TELO","fiscalQuarterEnding":"2024/12","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"post","actualEps":-0.1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TELO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TELO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TELO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TELO","date":"2026-03-31","current":-4,"percent":0.829588,"low":-83.265127,"twenty":-8.629277,"median":-5.638165,"eighty":-3.959451,"high":-2.36905,"avg":-9.093459,"sd":12.098123,"marketCap":39194306},"quantilePoints":[{"date":"2024-02-16","current":-56.39638,"twenty":-61.770129,"median":-49.049457,"eighty":-41.982417,"marketCap":238655100},{"date":"2024-02-23","current":-62.343889,"twenty":-63.029602,"median":-60.594622,"eighty":-46.922348,"marketCap":263823442},{"date":"2024-03-01","current":-63.46342,"twenty":-63.421438,"median":-62.588787,"eighty":-53.457611,"marketCap":268561012},{"date":"2024-03-08","current":-60.874505,"twenty":-63.351467,"median":-62.553802,"eighty":-58.915325,"marketCap":257605381},{"date":"2024-03-15","current":-45.550923,"twenty":-63.197532,"median":-61.749139,"eighty":-48.657621,"marketCap":192759889},{"date":"2024-03-22","current":-47.510102,"twenty":-63.029602,"median":-60.594622,"eighty":-45.928765,"marketCap":201050637},{"date":"2024-03-28","current":-35.580099,"twenty":-62.973626,"median":-56.39638,"eighty":-42.472212,"marketCap":150565904},{"date":"2024-04-05","current":-16.558518,"twenty":-62.833684,"median":-48.559663,"eighty":-36.881554,"marketCap":216450701},{"date":"2024-04-12","current":-18.574281,"twenty":-62.595784,"median":-46.390571,"eighty":-17.881143,"marketCap":242800474},{"date":"2024-04-19","current":-18.007992,"twenty":-62.469837,"median":-45.480952,"eighty":-18.234508,"marketCap":235398021},{"date":"2024-04-26","current":-15.402836,"twenty":-62.287913,"median":-41.632564,"eighty":-16.272973,"marketCap":201343774},{"date":"2024-05-03","current":-15.493668,"twenty":-61.8401,"median":-38.868721,"eighty":-15.530047,"marketCap":202531127},{"date":"2024-05-10","current":-14.814122,"twenty":-61.126399,"median":-34.985348,"eighty":-15.280653,"marketCap":193648183},{"date":"2024-05-17","current":-9.713938,"twenty":-60.762552,"median":-20.205194,"eighty":-14.460757,"marketCap":183044909},{"date":"2024-05-24","current":-9.899514,"twenty":-60.034856,"median":-18.959358,"eighty":-13.282876,"marketCap":186541828},{"date":"2024-05-31","current":-9.506677,"twenty":-58.635442,"median":-18.087272,"eighty":-12.474215,"marketCap":179139374},{"date":"2024-06-07","current":-8.846709,"twenty":-55.220872,"median":-16.988785,"eighty":-10.175947,"marketCap":166703252},{"date":"2024-06-14","current":-8.642433,"twenty":-50.224965,"median":-16.082609,"eighty":-9.764378,"marketCap":162853977},{"date":"2024-06-21","current":-8.249595,"twenty":-49.049457,"median":-15.652229,"eighty":-9.506677,"marketCap":155451523},{"date":"2024-06-28","current":-7.558201,"twenty":-48.069868,"median":-15.505107,"eighty":-8.846709,"marketCap":142423205},{"date":"2024-07-05","current":-6.803952,"twenty":-47.622055,"median":-15.431264,"eighty":-8.793283,"marketCap":128210494},{"date":"2024-07-12","current":-6.489682,"twenty":-46.614477,"median":-14.995334,"eighty":-8.611006,"marketCap":122288531},{"date":"2024-07-19","current":-5.892568,"twenty":-46.222641,"median":-14.134574,"eighty":-8.227596,"marketCap":111036802},{"date":"2024-07-26","current":-6.096844,"twenty":-45.67687,"median":-13.432376,"eighty":-7.822188,"marketCap":114886078},{"date":"2024-08-02","current":-5.248314,"twenty":-45.438969,"median":-12.639572,"eighty":-6.797667,"marketCap":98896778},{"date":"2024-08-09","current":-6.741098,"twenty":-44.067543,"median":-12.367753,"eighty":-6.690814,"marketCap":127026102},{"date":"2024-08-16","current":-6.303607,"twenty":-42.052388,"median":-10.284417,"eighty":-6.64996,"marketCap":118143157},{"date":"2024-08-23","current":-8.29422,"twenty":-40.401079,"median":-9.899514,"eighty":-6.678244,"marketCap":155451523},{"date":"2024-08-30","current":-8.278421,"twenty":-39.141606,"median":-9.736016,"eighty":-6.690814,"marketCap":155155425},{"date":"2024-09-06","current":-8.136234,"twenty":-38.861724,"median":-9.674022,"eighty":-6.712813,"marketCap":152490542},{"date":"2024-09-13","current":-9.589698,"twenty":-36.881554,"median":-9.506677,"eighty":-6.734812,"marketCap":179731570},{"date":"2024-09-20","current":-12.386034,"twenty":-35.223248,"median":-9.49882,"eighty":-6.759954,"marketCap":232140941},{"date":"2024-09-27","current":-10.774586,"twenty":-34.271647,"median":-9.637093,"eighty":-6.791381,"marketCap":201938931},{"date":"2024-10-04","current":-8.578593,"twenty":-25.750182,"median":-9.548188,"eighty":-6.888805,"marketCap":160781290},{"date":"2024-10-11","current":-8.009846,"twenty":-20.168951,"median":-9.479108,"eighty":-7.001943,"marketCap":150121756},{"date":"2024-10-18","current":-7.425301,"twenty":-19.534707,"median":-9.44751,"eighty":-7.071981,"marketCap":139166125},{"date":"2024-10-25","current":-7.01454,"twenty":-19.059025,"median":-9.384317,"eighty":-6.903527,"marketCap":131467574},{"date":"2024-11-01","current":-6.714368,"twenty":-18.728312,"median":-9.226332,"eighty":-6.834437,"marketCap":125841709},{"date":"2024-11-08","current":-6.666973,"twenty":-18.282076,"median":-8.941959,"eighty":-6.759954,"marketCap":124953415},{"date":"2024-11-15","current":-4.809979,"twenty":-18.039704,"median":-8.846709,"eighty":-6.708049,"marketCap":110444606},{"date":"2024-11-22","current":-5.467643,"twenty":-17.654627,"median":-8.799568,"eighty":-6.673736,"marketCap":125545611},{"date":"2024-11-29","current":-5.132363,"twenty":-17.074838,"median":-8.768141,"eighty":-6.632216,"marketCap":117847059},{"date":"2024-12-06","current":-8.407791,"twenty":-16.522185,"median":-8.642433,"eighty":-6.569924,"marketCap":193055987},{"date":"2024-12-13","current":-6.737953,"twenty":-16.313655,"median":-8.594391,"eighty":-6.600602,"marketCap":154713889},{"date":"2024-12-20","current":-6.712037,"twenty":-15.964821,"median":-8.461728,"eighty":-6.495967,"marketCap":154118835},{"date":"2024-12-27","current":-6.310352,"twenty":-15.760957,"median":-8.366804,"eighty":-6.403683,"marketCap":144895507},{"date":"2025-01-03","current":-5.856836,"twenty":-15.652229,"median":-8.303377,"eighty":-6.363974,"marketCap":134482072},{"date":"2025-01-10","current":-5.325574,"twenty":-15.570683,"median":-8.28632,"eighty":-6.315537,"marketCap":122283477},{"date":"2025-01-17","current":-6.077115,"twenty":-15.523297,"median":-8.249595,"eighty":-6.288654,"marketCap":139540026},{"date":"2025-01-24","current":-6.517673,"twenty":-15.50282,"median":-8.139601,"eighty":-6.28436,"marketCap":149655935},{"date":"2025-01-31","current":-6.297394,"twenty":-15.473282,"median":-8.073041,"eighty":-6.236001,"marketCap":144597981},{"date":"2025-02-07","current":-7.867,"twenty":-15.425578,"median":-8.088839,"eighty":-6.236001,"marketCap":130062872},{"date":"2025-02-14","current":-7.722981,"twenty":-15.280653,"median":-8.030693,"eighty":-6.247693,"marketCap":127681858},{"date":"2025-02-21","current":-7.038894,"twenty":-15.117652,"median":-7.97035,"eighty":-6.260979,"marketCap":116372043},{"date":"2025-02-28","current":-7.200915,"twenty":-14.922849,"median":-7.899257,"eighty":-6.280067,"marketCap":119050684},{"date":"2025-03-07","current":-7.830995,"twenty":-14.578546,"median":-7.867,"eighty":-6.294726,"marketCap":129467618},{"date":"2025-03-14","current":-8.245048,"twenty":-14.152696,"median":-7.888185,"eighty":-6.298884,"marketCap":136313033},{"date":"2025-03-21","current":-8.209043,"twenty":-13.908059,"median":-7.867,"eighty":-6.302115,"marketCap":135717779},{"date":"2025-03-28","current":-7.110904,"twenty":-13.595467,"median":-7.836063,"eighty":-6.306305,"marketCap":117562550},{"date":"2025-04-04","current":-5.27467,"twenty":-13.332709,"median":-7.821994,"eighty":-6.280067,"marketCap":87204626},{"date":"2025-04-11","current":-4.842615,"twenty":-12.988406,"median":-7.793903,"eighty":-6.226574,"marketCap":80061584},{"date":"2025-04-17","current":-4.464567,"twenty":-12.673549,"median":-7.741272,"eighty":-6.154861,"marketCap":73811424},{"date":"2025-04-25","current":-4.590583,"twenty":-12.555761,"median":-7.674628,"eighty":-6.056383,"marketCap":75894811},{"date":"2025-05-02","current":-4.662592,"twenty":-12.434833,"median":-7.63297,"eighty":-6.012327,"marketCap":77085317},{"date":"2025-05-09","current":-4.48257,"twenty":-12.382378,"median":-7.614926,"eighty":-5.935607,"marketCap":74109050},{"date":"2025-05-16","current":-5.972632,"twenty":-12.227313,"median":-7.558201,"eighty":-5.893196,"marketCap":74406677},{"date":"2025-05-23","current":-5.255916,"twenty":-11.632708,"median":-7.513523,"eighty":-5.862019,"marketCap":65477876},{"date":"2025-05-30","current":-5.017011,"twenty":-11.501318,"median":-7.475136,"eighty":-5.83092,"marketCap":62501609},{"date":"2025-06-06","current":-4.801996,"twenty":-11.15375,"median":-7.4411,"eighty":-5.738446,"marketCap":59822968},{"date":"2025-06-13","current":-4.778106,"twenty":-10.774586,"median":-7.421122,"eighty":-5.634716,"marketCap":59525342},{"date":"2025-06-20","current":-4.204733,"twenty":-10.62292,"median":-7.416943,"eighty":-5.48096,"marketCap":52382300},{"date":"2025-06-27","current":-4.06139,"twenty":-10.489162,"median":-7.344933,"eighty":-5.438999,"marketCap":50596540},{"date":"2025-07-03","current":-2.747411,"twenty":-10.309584,"median":-7.267316,"eighty":-5.403258,"marketCap":34227071},{"date":"2025-07-11","current":-2.795192,"twenty":-10.167924,"median":-7.19827,"eighty":-5.305212,"marketCap":34822325},{"date":"2025-07-18","current":-2.890754,"twenty":-10.119238,"median":-7.110904,"eighty":-5.252875,"marketCap":36012831},{"date":"2025-07-25","current":-5.470931,"twenty":-9.985876,"median":-7.051517,"eighty":-5.230053,"marketCap":68156516},{"date":"2025-08-01","current":-4.632645,"twenty":-9.902657,"median":-7.038894,"eighty":-5.134824,"marketCap":57713194},{"date":"2025-08-08","current":-4.137175,"twenty":-9.874769,"median":-6.990842,"eighty":-5.099417,"marketCap":51540660},{"date":"2025-08-15","current":-3.88944,"twenty":-9.817021,"median":-6.919749,"eighty":-5.017011,"marketCap":48454393},{"date":"2025-08-22","current":-3.011505,"twenty":-9.770664,"median":-6.814455,"eighty":-5.00486,"marketCap":48421455},{"date":"2025-08-29","current":-2.971351,"twenty":-9.7316,"median":-6.741098,"eighty":-4.932627,"marketCap":47775835},{"date":"2025-09-05","current":-2.489511,"twenty":-9.712744,"median":-6.725384,"eighty":-4.883224,"marketCap":40028402},{"date":"2025-09-12","current":-2.750508,"twenty":-9.681408,"median":-6.705303,"eighty":-4.805189,"marketCap":44224928},{"date":"2025-09-19","current":-2.810738,"twenty":-9.618135,"median":-6.678244,"eighty":-4.746437,"marketCap":45193358},{"date":"2025-09-26","current":-2.945698,"twenty":-9.55649,"median":-6.666973,"eighty":-4.681375,"marketCap":47363358},{"date":"2025-10-03","current":-2.924657,"twenty":-9.500391,"median":-6.651174,"eighty":-4.637423,"marketCap":47025048},{"date":"2025-10-10","current":-4.060855,"twenty":-9.486221,"median":-6.601898,"eighty":-4.590583,"marketCap":65293772},{"date":"2025-10-17","current":-3.408593,"twenty":-9.479108,"median":-6.517673,"eighty":-4.556077,"marketCap":54806171},{"date":"2025-10-24","current":-3.114023,"twenty":-9.472788,"median":-6.471284,"eighty":-4.524565,"marketCap":50069835},{"date":"2025-10-31","current":-3.156105,"twenty":-9.45067,"median":-6.414196,"eighty":-4.48257,"marketCap":50746455},{"date":"2025-11-07","current":-2.840494,"twenty":-9.412754,"median":-6.396899,"eighty":-4.45201,"marketCap":45671809},{"date":"2025-11-14","current":-3.909223,"twenty":-9.384317,"median":-6.363974,"eighty":-4.258858,"marketCap":43980261},{"date":"2025-11-21","current":-4.247815,"twenty":-9.364121,"median":-6.343714,"eighty":-4.249695,"marketCap":47789549},{"date":"2025-11-28","current":-4.095016,"twenty":-9.331287,"median":-6.313593,"eighty":-4.204733,"marketCap":46070501},{"date":"2025-12-05","current":-4.156135,"twenty":-9.283207,"median":-6.30112,"eighty":-4.101128,"marketCap":46758120},{"date":"2025-12-12","current":-4.522853,"twenty":-9.116263,"median":-6.282214,"eighty":-4.127895,"marketCap":50883837},{"date":"2025-12-19","current":-4.186695,"twenty":-9.035462,"median":-6.238265,"eighty":-4.127895,"marketCap":47101930},{"date":"2025-12-26","current":-4.339494,"twenty":-8.956704,"median":-6.222552,"eighty":-4.137175,"marketCap":48820978},{"date":"2026-01-02","current":-4.064456,"twenty":-8.944908,"median":-6.154861,"eighty":-4.119463,"marketCap":45726691},{"date":"2026-01-09","current":-4.339494,"twenty":-8.902896,"median":-6.1047,"eighty":-4.119463,"marketCap":48820978},{"date":"2026-01-16","current":-4.186695,"twenty":-8.85636,"median":-6.068194,"eighty":-4.119463,"marketCap":47101930},{"date":"2026-01-23","current":-4.095016,"twenty":-8.846892,"median":-6.038242,"eighty":-4.095016,"marketCap":46070501},{"date":"2026-01-30","current":-3.728298,"twenty":-8.846709,"median":-6.012327,"eighty":-4.082792,"marketCap":41944784},{"date":"2026-02-06","current":-3.422699,"twenty":-8.828026,"median":-5.986849,"eighty":-4.06323,"marketCap":38506687},{"date":"2026-02-13","current":-3.30046,"twenty":-8.805969,"median":-5.937145,"eighty":-4.036058,"marketCap":37131448},{"date":"2026-02-20","current":-3.453259,"twenty":-8.799568,"median":-5.894139,"eighty":-4.033896,"marketCap":38850497},{"date":"2026-02-27","current":-4.003336,"twenty":-8.786997,"median":-5.882751,"eighty":-3.950834,"marketCap":45039072},{"date":"2026-03-06","current":-3.972776,"twenty":-8.724143,"median":-5.850357,"eighty":-3.942216,"marketCap":44695262},{"date":"2026-03-13","current":-4.278374,"twenty":-8.651861,"median":-5.814739,"eighty":-3.942216,"marketCap":48133359},{"date":"2026-03-20","current":-4.358205,"twenty":-8.642433,"median":-5.751341,"eighty":-3.950834,"marketCap":45382881},{"date":"2026-03-27","current":-4.160105,"twenty":-8.635855,"median":-5.672579,"eighty":-3.967366,"marketCap":43320023},{"date":"2026-03-31","current":-3.763904,"twenty":-8.629277,"median":-5.638165,"eighty":-3.959451,"marketCap":39194306}],"updateTime":1775117043634},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TELO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592943683","title":"Telomir Pharmaceuticals Reports Positive Safety Results for Lead Drug Candidate Telomir-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943683","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943683?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:02","pubTimestamp":1766005343,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced favorable results from a series of Good Laboratory Practice  toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 . The studies, conducted in both in vitro systems and in vivo rat and dog models, found that Telomir-1 was generally well tolerated, with no treatment-related or dose-limiting toxicities observed. The company reported no adverse effects on cardiovascular, respiratory, or phototoxicity parameters, and any observed findings were limited, reversible, and considered non-adverse. Telomir Pharmaceuticals is preparing for the submission of an Investigational New Drug  application in the first quarter of 2026 and anticipates beginning first-in-human clinical studies in the first half of 2026. The company is also planning to submit scientific manuscripts for publication and to present data at multiple oncology-focused scientific conferences in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL3gc2fw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586649089","title":"Telomir-1 Lowers PSA Levels and Reduces Tumor Volume in Prostate Cancer Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2586649089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586649089?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:02","pubTimestamp":1764018141,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new preclinical data showing that its investigational compound, Telomir-1, significantly reduces prostate-specific antigen  levels in androgen-responsive human prostate cancer cells in vitro. PSA is an FDA-recognized biomarker for assessing prostate cancer treatment response, and Telomir-1 was found to lower PSA levels in a dose-dependent manner. The compound also demonstrated reductions in cellular energy metabolism and viability. Additional previously reported preclinical studies in a mouse model showed that Telomir-1 reduced tumor volume, both as a single agent and in combination with paclitaxel, with the combination resulting in no treatment-related mortality. These findings are part of Telomir's ongoing preclinical development efforts as the company prepares for an investigational new drug  submission. The announcement did not specify if or when these results will be presented at a scientific meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6hfvf7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585633091","title":"Telomir Pharmaceuticals Director Craig Eagle Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2585633091","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585633091?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:16","pubTimestamp":1763676964,"startTime":"0","endTime":"0","summary":"Craig Eagle has resigned from the Board of Directors of Telomir Pharmaceuticals Inc., effective immediately.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL8YtdD9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585829168","title":"Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2585829168","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585829168?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:35","pubTimestamp":1763674516,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). Telomir Pharmaceuticals announced that its investigational compound,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-telomir-1-shows-leukemia-efficacy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-telomir-1-shows-leukemia-efficacy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585150586","title":"Telomir Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150586","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150586?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:18","pubTimestamp":1763673505,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. will hold its Annual Meeting exclusively online via live audio-only webcast on December 30, 2025. During the meeting, stockholders will vote on matters submitted for approval, including proposals related to the business and operations of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL108vXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585157421","title":"Telomir-1 Kills Aggressive Human Leukemia Cells in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157421?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:02","pubTimestamp":1763672558,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new in vitro research results showing that its investigational compound, Telomir-1, effectively kills aggressive human leukemia  cells. These findings expand the oncology profile of Telomir-1 to include blood cancers, adding to previous evidence of activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The study demonstrated that Telomir-1 reduces leukemia cell viability in a clear, dose-dependent manner and uniquely lowers intracellular iron levels, which leukemia cells rely on for growth and survival. The compound also inhibits key histone-demethylase enzymes and reduces abnormal DNA methylation of tumor-suppressor genes, supporting further oncology research by the company. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL42980W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582174376","title":"Telomir Pharmaceuticals Unveils Promising Preclinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2582174376","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582174376?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:38","pubTimestamp":1762951118,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). Telomir Pharmaceuticals, Inc. has announced new preclinical data ind...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-unveils-promising-preclinical-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-unveils-promising-preclinical-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582375882","title":"Telomir-1 Outperforms Deferoxamine in Reducing Intracellular Iron in Human Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375882?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948957,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new preclinical research results showing that its lead investigational compound, Telomir-1, significantly outperformed the FDA-approved iron chelator Deferoxamine  in reducing intracellular iron levels in human keratinocyte  cells. According to the company, live-cell imaging data demonstrated that Telomir-1 achieved a strong, dose-dependent reduction in intracellular iron at submicromolar concentrations, highlighting its potent cell penetration and iron-modulating capabilities. The announcement did not specify if or when these results will be presented at a scientific meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to gen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8SzYhD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582389325","title":"Telomir Pharmaceuticals Q3 EPS $(0.03) Beats $(0.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582389325","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582389325?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:00","pubTimestamp":1762815621,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals (NASDAQ:TELO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 85 percent increase over losses of $(0.20) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48769754/telomir-pharmaceuticals-q3-eps-0-03-beats-0-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Telomir Pharmaceuticals Q3 EPS $(0.03) Beats $(0.07) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581183209","title":"Telomir Pharmaceuticals Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581183209","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581183209?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:56","pubTimestamp":1762556178,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc  expected to post a loss of7cents a share - Earnings Preview Telomir Pharmaceuticals Inc TELO.OQ TELO.O is expected to  report resultson November 10 (estimated) for the per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ324:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577311174","title":"Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2577311174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577311174?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:40","pubTimestamp":1761165635,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). On October 22, 2025, Telomir Pharmaceuticals announced preclinical d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-unveils-promising-preclinical-cancer-data-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-unveils-promising-preclinical-cancer-data-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577131542","title":"Telomir Pharmaceuticals Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2577131542","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577131542?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:02","pubTimestamp":1761163357,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new preclinical data from a study evaluating its investigational compound, Telomir-1, in an aggressive prostate cancer model. The results, which have already been reported by the company, indicate that Telomir-1 reduces DNA methylation of the CASP8 and GSTP1 genes-both of which regulate key cell death and detoxification pathways often disrupted in cancer. Compared to chemotherapy and the mTOR pathway inhibitor Rapamycin, Telomir-1 demonstrated a more sustained reduction in DNA methylation over a 21-day period. The company noted that combined therapy with Telomir-1 and chemotherapy showed lower methylation levels than chemotherapy alone, suggesting potential for enhanced epigenetic effects. These findings may inform ongoing research on Telomir-1 in oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL3qRFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577943608","title":"Telomir Pharmaceuticals to Acquire TELI Pharmaceuticals in Stock-for-Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2577943608","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577943608?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:48","pubTimestamp":1761000532,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals, Inc. has entered into a binding Letter of Intent with TELI Pharmaceuticals, Inc. to acquire all outstanding shares of TELI through a stock-for-stock exchange. The agreement will consolidate worldwide intellectual property and development rights for Telomir-1, an oral epigenetic therapy in preclinical development for cancer, aging, and age-related diseases. The exchange ratio for the shares will be determined by an independent third-party valuation. Certain TELI shareholders have committed up to $5 million in cash contributions to support the transaction and future development, with milestone-based payments tied to regulatory and clinical progress for Telomir-1. The agreement includes a six-month lockup period for the shares to be issued and unifies global rights to streamline development and partnership activities. Completion remains subject to due diligence, approvals, and execution of definitive agreements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL86BlLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577994258","title":"Telomir Pharmaceuticals: on Oct 17, Entered Loi to Acquire All Shares of Teli Pharmaceuticals Through Stock-for-Stock Exchange - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577994258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577994258?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:03","pubTimestamp":1760997822,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577899712","title":"Telomir Pharmaceuticals: Loi Provides for 6-Month Lockup Period on Telomir Shares to Be Issued to Teli Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2577899712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577899712?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:03","pubTimestamp":1760997822,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0DE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577899242","title":"Telomir Pharmaceuticals: Transaction Consolidates Global Rights to Telmir-1 for Cancer and Aging","url":"https://stock-news.laohu8.com/highlight/detail?id=2577899242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577899242?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:03","pubTimestamp":1760997822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0DE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575292387","title":"Telomir Pharmaceuticals Reports Telomir-1 Kills Aggressive Pancreatic Cancer Cells in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2575292387","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575292387?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:31","pubTimestamp":1760441483,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new laboratory findings showing that its investigational compound, Telomir-1, significantly reduces the survival of aggressive human pancreatic cancer  cells in vitro. The data revealed a concentration-dependent decrease in cancer cell viability and mitochondrial activity, suggesting that Telomir-1 affects cellular pathways related to energy metabolism and oxidative balance. These results are consistent with previously reported effects in triple-negative breast cancer and prostate cancer models. Telomir-1's action appears to involve modulation of epigenetic and metabolic regulators, including tumor suppressor genes and iron-dependent enzymes relevant to pancreatic cancer. The company plans to expand preclinical research to additional cancer models and begin in vivo validation studies as part of its IND preparation. The company did not specify if or when these results will be presented at a scientific meeting.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7yqRnR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2574168454","title":"Telomir Pharmaceuticals Shares up 24% After Co Reports Breast Cancer Therapy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2574168454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574168454?lang=en_us&edition=fundamental","pubTime":"2025-10-09 21:32","pubTimestamp":1760016751,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VQ1C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2574972825","title":"Telomir Pharmaceuticals Inc: Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2574972825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574972825?lang=en_us&edition=fundamental","pubTime":"2025-10-09 04:05","pubTimestamp":1759953918,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP23S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2574725999","title":"Telomir Pharmaceuticals: Plans to Expand Studies to Pancreatic, Leukemia Models, Conduct Further Animal Studies for Ind Submission - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2574725999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574725999?lang=en_us&edition=fundamental","pubTime":"2025-10-09 04:05","pubTimestamp":1759953918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP23S:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}]}}